203 related articles for article (PubMed ID: 18078011)
1. Aldosterone antagonism in heart failure.
Miller AB
Vasc Health Risk Manag; 2007; 3(5):605-9. PubMed ID: 18078011
[TBL] [Abstract][Full Text] [Related]
2. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
4. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Nappi JM; Sieg A
Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
[TBL] [Abstract][Full Text] [Related]
6. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Verma A; Solomon SD
Curr Heart Fail Rep; 2007 Dec; 4(4):183-9. PubMed ID: 18221614
[TBL] [Abstract][Full Text] [Related]
7. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
Salam AM
Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone in the treatment of chronic heart failure.
Krum H; Liew D
Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
[TBL] [Abstract][Full Text] [Related]
9. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
10. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
12. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
14. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
[No Abstract] [Full Text] [Related]
15. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
de Pouvourville G; Solesse A; Beillat M
Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
[TBL] [Abstract][Full Text] [Related]
17. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
Fügedi K
Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
19. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
